A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

1145

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to safety issues.

Conditions

Alzheimers Disease

Interventions

DRUG: CNP520 50mg
DRUG: CNP520 15mg
OTHER: Matching placebo

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]
[object Object]